<DOC>
	<DOCNO>NCT00000972</DOCNO>
	<brief_summary>To evaluate safety fix antigen dose increase dose adjuvant ( MTP-PE/MF59 , substance enhance immune response vaccine ) volunteer . To evaluate local systemic reaction ( Part A ) . To determine safety immunogenicity Env 2-3 combination MTP-PE/MF59 volunteer ( Part B ) . The vaccine Env 2-3 create one viral protein make HIV call envelope glycoprotein gp120 . A problem many immunogen , include candidate HIV vaccine , may evoke relatively weak immune response , particularly human nonhuman primate . Thus , considerable interest development `` adjuvant '' ( substance augment immune response vaccine ) . MTP-PE/MF59 adjuvant appear particularly promising , select study HIV vaccine candidate .</brief_summary>
	<brief_title>A Phase I Clinical Trial Evaluate : Part A . The Safety MTP-PE/MF59 Adjuvant Emulsion . Part B . The Safety Immunogenicity Env 2-3 , Yeast Derived Recombinant Envelope Protein Human Immunodeficiency Virus-1 , Combination With MTP-PE/MF59</brief_title>
	<detailed_description>The vaccine Env 2-3 create one viral protein make HIV call envelope glycoprotein gp120 . A problem many immunogen , include candidate HIV vaccine , may evoke relatively weak immune response , particularly human nonhuman primate . Thus , considerable interest development `` adjuvant '' ( substance augment immune response vaccine ) . MTP-PE/MF59 adjuvant appear particularly promising , select study HIV vaccine candidate . This study conduct two part : Part A examines safety adjuvant MTP-PE/MF59 alone ; Part B examine safety immunogenicity Env 2-3 combination MTP-PE/MF59 . In Part A , three volunteer receive MTP-PE/MF59 , one volunteer receive emulsion alone dose level . Initiation dose level separate least 72 hour . Doses adjuvant emulsion administer day 0 day 30 high tolerate dose . If significant reaction encounter , additional subject may study low dos . In Part B , six dos MTP-PE adjuvant ( 0 , 5 , 10 , 25 , 50 , 100 mcg ) MF59 emulsion study . Six volunteer receive Env 2-3/MTP-PE/MF59 two receive MTP-PE/MF59 alone dose level . There minimum 1-week interval dose escalation . Per amendment , volunteer may receive additional dose Env 2-3 placebo MF59 emulsion , administer 12-18 month post initial inoculation .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<mesh_term>Mifamurtide</mesh_term>
	<criteria>Inclusion Criteria Volunteers : Normal , healthy adult ( history physical examination ) fully comprehend purpose detail study . Part A : Available 60 day . Part B : Available 1 year followup . Exclusion Criteria Coexisting Condition : Volunteers follow condition symptom exclude : Part B : Positive syphilis serology ( VDRL ) unless positive test due document clinical event occur treated 5 year prior enrollment . Circulating hepatitis B antigenemia . Volunteers follow exclude : History immunodeficiency , chronic illness , autoimmune disease . Evidence depression treatment psychiatric problem past year . Prior Medication : Excluded : Immunosuppressive medication . Prior Treatment : Excluded : Part B : Blood transfusion cryoprecipitates within past 6 month . Risk Behavior : Excluded : Part B : Identifiable highrisk behavior HIV infection , include : history intravenous drug use ; syphilis , gonorrhea , sexually transmit disease ( include chlamydia pelvic inflammatory disease ) last 6 month ; two sexual partner , sexual contact highrisk partner , precede 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Adjuvants , Immunologic</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>